Phase 2 trial of carboplatin plus tamoxifen in platinum-resistant ovarian cancer and primary carcinoma of the peritoneum

Gynecologic Oncology

Volumn 94, Issue 2, 2004, Pages 404-408

  Markman, Maurie ^a   Webster, Kenneth ^b   Zanotti, Kristine ^b   Peterson, Gertrude ^b   Kulp, Barbara ^b   Belinson, Jerome ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b NONE

Author keywords

Cancer chemotherapy; Carboplatin; Ovarian cancer; Tamoxifen

Indexed keywords

CARBOPLATIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAMOXIFEN;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG TOLERABILITY; DRUG TOXICITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MEDICAL DOCUMENTATION; OVARY CARCINOMA; PERITONEUM CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SAMPLE SIZE; THROMBOCYTOPENIA; TREATMENT FAILURE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CISPLATIN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; TAMOXIFEN;

EID: 3543081555     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.05.004     Document Type: Article

References (22)

1. McGuire W.P., Hoskins W.J., Brady M.F., Kucera P.R., Partridge E.E., Look K.Y., et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer. N. Engl. J. Med. 334:1996;1-6
2. Markman M. Optimizing primary chemotherapy in ovarian cancer. Hematol. Oncol. Clin. North Am. 17:2003;957-968
3. Ozols R.F., O'Dwyer P.J., Hamilton T.C. Clinical reversal of drug resistance in ovarian cancer. Gynecol. Oncol. 51:1993;90-96
4. Perez R.P., Hamilton T.C., Ozols R.F., Young R.C. Mechanisms and modulation of resistance to chemotherapy in ovarian cancer. Cancer. 71:1993;1571-1580
5. Ozols R.F., Cunnion R.E., Klecker R.W. Jr., Hamilton T.C., Ostchega Y., Parrillo J.E., et al. Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J. Clin. Oncol. 5:1987;641-647
6. Bissett D., Kerr D.J., Cassidy J., Meredith P., Traugott U., Kaye S.B. Phase I and pharmacokinetic study of D-verapamil and doxorubicin. Br. J. Cancer. 64:1991;1168-1171
7. Panasci L., Jean-Claude B.J., Vasilescu D., Mustafa A., Damian S., Damian Z., et al. Sensitization to doxorubicin resistance in breast cancer cell lines by tamoxifen and megestrol acetate. Biochem. Pharmacol. 52:1996;1097-1102
8. McClay E.F., Albright K.D., Jones J.A., Christen R.D., Howell S.B. Tamoxifen modulation of cisplatin cytotoxicity in human malignancies. Int. J. Cancer. 55:1993;1018-1022
9. Geisinger K.R., Berens M.E., Duckett Y., Morgan T.M., Kute T.E., Welander C.E. The effects of estrogen, progesterone, and tamoxifen alone and in combination with cytotoxic agents against human ovarian carcinoma in vitro. Cancer. 65:1990;1055-1061
10. McClay E.F., Albright K.D., Jones J.A., Eastman A., Christen R., Howell S.B. Modulation of cisplatin resistance in human malignant melanoma cells. Cancer Res. 52:1992;6790-6796
11. McClay E.F., Albright K.D., Jones J.A., Christen R.D., Howell S.B. Tamoxifen modulation of cisplatin sensitivity in human malignant melanoma cells. Cancer Res. 53:1993;1571-1576
12. McClay E.F., Albright K.D., Jones J.A., Christen R.D., Howell S.B. Tamoxifen delays the development of resistance to cisplatin in human melanoma and ovarian cancer cell lines. Br. J. Cancer. 70:1994;449-452
13. Benedetti Panici P., Greggi S., Amoroso M., Scambia G., Battaglia F.A., Gebbia V., et al. A combination of platinum and tamoxifen in advanced ovarian cancer failing platinum-based chemotherapy: results of a phase II study. Int. J. Gynaecol. Cancer. 11:2001;438-444
14. Markman M., Hall J., Spitz D., Weiner S., Carson L., Van Le L., et al. Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel- refractory ovarian cancer. J. Clin. Oncol. 20:2002;2365-2369
15. Markman M., Webster K., Zanotti K., Kulp B., Peterson G., Belinson J. Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer. Gynecol. Oncol. 90:2003;593-596
16. Bridgewater J.A., Nelstrop A.E., Rustin G.J.S., Gore M.E., McGuire W.P., Hoskins W.J. Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel. J. Clin. Oncol. 17:1999;501-508
17. Thigpen J.T., Blessing J.A., Ball H., Hummel S.J., Barrett R.J. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. J. Clin. Oncol. 12:1994;1748-1753
18. Markman M., Kennedy A., Webster K., Kulp B., Peterson G., Belinson J. Evidence that a "treatment-free interval of less than 6 months" does not equate with clinically defined platinum resistance in ovarian cancer or primary peritoneal carcinoma. J. Cancer Res. Clin. Oncol. 124:1998;326-328
19. Ahlgren J.D., Ellison N.M., Gottlieb R.J., Laluna F., Lokich J.J., Sinclair P.R., et al. Hormonal palliation of chemoresistant ovarian cancer: three consecutive phase II trials of the Mid-Atlantic Oncology Program. J. Clin. Oncol. 11:1993;1957-1968
20. Marth C., Sorheim N., Kaern J., Trope C. Tamoxifen in the treatment of recurrent ovarian carcinoma. Int. J. Gynaecol. Cancer. 7:1997;256-261
21. Markman M., Iseminger K.A., Hatch K.D., Creasman W.T., Barnes W., Dubeshter B. Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group ancillary report. Gynecol. Oncol. 62:1996;4-6
22. Perez-Gracia J.L., Carrasco E.M. Tamoxifen therapy for ovarian cancer in the adjuvant and advanced settings: systematic review of the literature and implications for future research. Gynecol. Oncol. 84:2002;201-209